Figs Inc

Figs Inc (FIGS) Stock Analysis

$15.420

+0.327 (+2.12%)At close

Loading chart…
High
15.610
Open
15.210
VWAP
15.39
Vol
2.22M
Mkt Cap
890.29M
Low
15.130
Amount
34.23M
EV/EBITDA, TTM
15.57

FIGS, Inc. is a direct-to-consumer healthcare apparel and lifestyle brand. It designs and sells scrub wear and non-scrub wear, such as outerwear, under scrubs, footwear, compression socks, lab coats, lounge wear and other apparel. It markets and sells its products primarily in the United States. It designs all its products in-house, leverages third-party suppliers and manufacturers to produce its product components and finished products, and generally uses shallow initial buys and data-driven repurchasing decisions to test new products. It directly and actively coordinates with its suppliers at every step of its product development and production process to ensure that its quality standards are met. Its under scrubs include performance tops, and super-soft Pima cotton tops. Its outer layer products include footwear, lab coats and a variety of vests, jackets and fleeces. Its non-scrub wear product offerings include its lounge wear, which is its collection designed for off-shift moments.

AI analysis of Figs Inc (FIGS)

buy

Figs Inc is a good buy right now due to its recent strong performance, including a 29% year-over-year sales increase to $196.6 million in Q2 2026, and a significant rise in net income to $28.4 million in the same quarter. The stock's current price of $15.42 is well below the average analyst price target of $20, suggesting a potential upside of 29%. However, the main risk is the forward P/E ratio of 49.02, which indicates that the stock may be overvalued if growth does not meet expectations.

Valuation Metrics

The current forward P/E ratio for Figs Inc (FIGS) is 49.02, compared to its 5-year average forward P/E of 92.60.

Forward P/E

Undervalued
5Y Average P/E
92.60
Current P/E
49.02
Overvalued
130.47
Undervalued
54.72

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
22.57
Current EV/EBITDA
15.57
Overvalued
38.11
Undervalued
7.03

Forward P/S

Fair
5Y Average P/S
3.08
Current P/S
3.06
Overvalued
5.74
Undervalued
0.42

Alphio AI Price Scenarios for FIGS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%FIGS

$4.85

Scenario price

B

Base

Base · 50%FIGS

$4.52

Scenario price

B

Bear

Bear · 25%FIGS

$4.18

Scenario price

Whales holding FIGS

D

Divisadero Street Capital Management, LP

+ HoldingFIGS

+7.83%

3M Return

Events Timeline

2026-08-06 (ET)

19:00:00

Stock Futures Mixed as Doximity Soars 83.93%

17:00:00

FIGS Reports Q2 Revenue of $196.6M, Beating Expectations

17:00:00

Raises FY26 Adjusted EBITDA Margin View to 14.8%-15%

2026-05-08 (ET)

12:10:00

Figs Shares Drop 28% to $11.06

10:10:00

Figs Stock Drops 25.8% to $11.40

News

FIGS FAQ — answered by Alphio AI

FIGS, Inc. is a direct-to-consumer healthcare apparel and lifestyle brand. It designs and sells scrub wear and non-scrub wear, such as outerwear, under scrubs, footwear, compression socks, lab coats, lounge wear and other apparel. It markets and sells its products primarily in the United States. It designs all its products in-house, leverages third-party suppliers and manufacturers to produce its product components and finished products, and generally uses shallow initial buys and data-driven repurchasing decisions to test new products. It directly and actively coordinates with its suppliers at every step of its product development and production process to ensure that its quality standards are met. Its under scrubs include performance tops, and super-soft Pima cotton tops. Its outer layer products include footwear, lab coats and a variety of vests, jackets and fleeces. Its non-scrub wear product offerings include its lounge wear, which is its collection designed for off-shift moments. It operates in the Consumer Cyclicals sector (APPAREL & OTHER FINISHD PRODS OF FABRICS & SIMILAR industry).

Figs Inc is a good buy right now due to its recent strong performance, including a 29% year-over-year sales increase to $196.6 million in Q2 2026, and a significant rise in net income to $28.4 million in the same quarter. The stock's current price of $15.42 is well below the average analyst price target of $20, suggesting a potential upside of 29%. However, the main risk is the forward P/E ratio of 49.02, which indicates that the stock may be overvalued if growth does not meet expectations.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis